Vitamin D-binding protein interacts with Aβ and suppresses Aβ-mediated pathology

Cell Death and Differentiation

Volumn 20, Issue 4, 2013, Pages 630-638

  Moon, M ^a   Song, H ^a   Hong, H J ^a   Nam, D W ^a   Cha, M Y ^a   Oh, M S ^b   Yu, J ^a   Ryu, H ^c,d   Mook Jung, I ^a  

^a Seoul National University   (South Korea)

^b Kyung Hee University   (South Korea)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Seoul National University College of Medicine   (South Korea)

Author keywords

Alzheimer's disease; Amyloid beta; Cytotoxicity; Neurodegeneration; Vitamin D binding protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; VITAMIN D BINDING PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC FORCE MICROSCOPY; CELL DEATH; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROTEIN INTERACTION; SURFACE PLASMON RESONANCE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOPTOSIS; BEHAVIOR, ANIMAL; BRAIN; CELL LINE; HIPPOCAMPUS; HUMANS; MALE; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PROTEIN BINDING; RECOMBINANT PROTEINS; SYNAPTOPHYSIN; VITAMIN D-BINDING PROTEIN;

MUS;

EID: 84874945336     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2012.161     Document Type: Article

References (56)

1. Selkoe DJ. Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol 1994; 53: 438-447.
2. Sakono M, Zako T. Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J 2010; 277: 1348-1358.
3. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005; 8: 79-84.
4. Golde TE, Schneider LS, Koo EH. Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 2011; 69: 203-213.
5. Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P et al. Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci USA 2008; 105: 2681-2686.
6. DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW et al. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 2004; 41: 193-202.
7. Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, Klein AM et al. Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. Nat Genet 2007; 39: 1440-1442.
8. Bohrmann B, Tjernberg L, Kuner P, Poli S, Levet-Trafit B, Naslund J et al. Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for betaamyloid formation in the central nervous system and in peripheral tissues. J Biol Chem 1999; 274: 15990-15995.
9. White P, Cooke N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metab 2000; 11: 320-327.
10. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006; 372: 33-42.
11. Gressner OA, Schifflers MC, Kim P, Heuts L, Lahme B, Gressner AM. Questioning the role of actinfree Gc-globulin as actin scavenger in neurodegenerative central nervous system disease: relationship to S-100B levels and blood-brain barrier function. Clin Chim Acta 2009; 400: 86-90.
12. Gomme PT, Bertolini J. Therapeutic potential of vitamin D-binding protein. Trends Biotechnol 2004; 22: 340-345.
13. Meier U, Gressner O, Lammert F, Gressner AM. Gc-globulin: roles in response to injury. Clin Chem 2006; 52: 1247-1253.
14. Blanton D, Han Z, Bierschenk L, Linga-Reddy MV, Wang H, Clare-Salzler M et al. Reduced serum vitamin d-binding protein levels are associated with type 1 diabetes. Diabetes 2011; 60: 2566-2570.
15. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 2006; 9: 293-348.
16. Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 2008; 129: 526-529.
17. Chauhan A, Pirttila T, Mehta P, Chauhan VP, Wisniewski HM. Effect of cerebrospinal fluid from normal and Alzheimer's patients with different apolipoprotein E phenotypes on in vitro aggregation of amyloid beta-protein. J Neurol Sci 1996; 141: 54-58.
18. Jirikowski GF, Kaunzner UW, Dief Ael E, Caldwell JD. Distribution of vitamin D binding protein expressing neurons in the rat hypothalamus. Histochem Cell Biol 2009; 131: 365-370.
19. Wilhelmus MM, Boelens WC, Otte-Holler I, Kamps B, de Waal RM, Verbeek MM. Small heat shock proteins inhibit amyloid-beta protein aggregation and cerebrovascular amyloidbeta protein toxicity. Brain Res 2006; 1089: 67-78.
20. Ray I, Chauhan A, Wegiel J, Chauhan VP. Gelsolin inhibits the fibrillization of amyloid betaprotein, and also defibrillizes its preformed fibrils. Brain Res 2000; 853: 344-351.
21. Selenica ML, Wang X, Ostergaard-Pedersen L, Westlind-Danielsson A, Grubb A. Cystatin C reduces the in vitro formation of soluble Abeta1-42 oligomers and protofibrils. Scand J Clin Lab Invest 2007; 67: 179-190.
22. Moon M, Choi JG, Nam DW, Hong HS, Choi YJ, Oh MS et al. Ghrelin ameliorates cognitive dysfunction and neurodegeneration in intrahippocampal amyloid-beta1-42 oligomerinjected mice. J Alzheimers Dis 2011; 23: 147-159.
23. West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 1994; 344: 769-772.
24. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K et al. A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 2010; 30: 4845-4856.
25. Wilhelmus MM, de Waal RM, Verbeek MM. Heat shock proteins and amateur chaperones in amyloid-beta accumulation and clearance in Alzheimer's disease. Mol Neurobiol 2007; 35: 203-216.
26. Ferreira ST, Klein WL. The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem 2011; 96: 529-543.
27. Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E et al. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol 2006; 60: 668-676.
28. Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging 1990; 11: 29-37.
29. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr. et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 2001; 56: 127-129.
30. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-580.
31. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007; 27: 796-807.
32. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 2007; 61: 120-129.
33. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992; 359: 325-327.
34. Qin Z, Qin Y, Liu S. Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell Mol Neurobiol 2009; 29: 203-210.
35. Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F et al. A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 2002; 99: 16742-16747.
36. Reinke AA, Gestwicki JE. Insight into amyloid structure using chemical probes. Chem Biol Drug Des 2011; 77: 399-411.
37. Chambon C, Wegener N, Gravius A, Danysz W. Behavioural and cellular effects of exogenous amyloid-beta peptides in rodents. Behav Brain Res 2011; 225: 623-641.
38. Han SH, Jung ES, Sohn JH, Hong HJ, Hong HS, Kim JW et al. Human serum transthyretin levels correlate inversely with Alzheimer's disease. J Alzheimers Dis 2011; 25: 77-84.
39. Hansson SF, Andreasson U, Wall M, Skoog I, Andreasen N, Wallin A et al. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J Alzheimers Dis 2009; 16: 389-397.
40. Fernandez-Montesinos R, Torres M, Baglietto-Vargas D, Gutierrez A, Gozes I, Vitorica J et al. Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. J Mol Neurosci 41: 114-120.
41. Tizon B, Ribe EM, Mi W, Troy CM, Levy E. Cystatin C protects neuronal cells from amyloidbeta- induced toxicity. J Alzheimers Dis 19: 885-894.
42. Merched A, Serot JM, Visvikis S, Aguillon D, Faure G, Siest G. Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry. FEBS Lett 1998; 425: 225-228.
43. Pogge E. Vitamin D and Alzheimer's disease: is there a link? Consult Pharm 2010; 25: 440-450.
44. Paris D, Patel N, DelleDonne A, Quadros A, Smeed R, Mullan M. Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci Lett 2004; 366: 80-85.
45. Mattson MP. Oxidative stress, perturbed calcium homeostasis, and immune dysfunction in Alzheimer's disease. J Neurovirol 2002; 8: 539-550.
46. Raymond MA, Desormeaux A, Labelle A, Soulez M, Soulez G, Langelier Y et al. Endothelial stress induces the release of vitamin D-binding protein, a novel growth factor. Biochem Biophys Res Commun 2005; 338: 1374-1382.
47. Maezawa I, Hong HS, Liu R, Wu CY, Cheng RH, Kung MP et al. Congo red and thioflavin-T analogs detect Abeta oligomers. J Neurochem 2008; 104: 457-468.
48. Maezawa I, Hong HS, Wu HC, Battina SK, Rana S, Iwamoto T et al. A novel tricyclic pyrone compound ameliorates cell death associated with intracellular amyloid-beta oligomeric complexes. J Neurochem 2006; 98: 57-67.
49. Hong HS, Rana S, Barrigan L, Shi A, Zhang Y, Zhou F et al. Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo. J Neurochem 2009; 108: 1097-1108.
50. Lee KH, Shin BH, Shin KJ, Kim DJ, Yu J. A hybrid molecule that prohibits amyloid fibrils and alleviates neuronal toxicity induced by beta-amyloid (1-42). Biochem Biophys Res Commun 2005; 328: 816-823.
51. Bang OY, Hong HS, Kim DH, Kim H, Boo JH, Huh K et al. Neuroprotective effect of genistein against beta amyloid-induced neurotoxicity. Neurobiol Dis 2004; 16: 21-28.
52. Grohm J, Kim SW, Mamrak U, Tobaben S, Cassidy-Stone A, Nunnari J et al. Inhibition of Drp1 provides neuroprotection in vitro and in vivo. Cell Death Differ 2012; 19: 1446-1458.
53. Yang W, Dunlap JR, Andrews RB, Wetzel R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet 2002; 11: 2905-2917.
54. Paxinos G, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates. 2nd edn Academic Press: San Diego, CA, 2001.
55. Kim DH, Jeon SJ, Son KH, Jung JW, Lee S, Yoon BH et al. The ameliorating effect of oroxylin A on scopolamine-induced memory impairment in mice. Neurobiol Learn Mem 2007; 87: 536-546.
56. Moon M, Hong HS, Nam DW, Baik SH, Song H, Kook SY et al. Intracellular amyloid-beta accumulation in calcium-binding protein-deficient neurons leads to amyloid-beta plaque formation in animal models of Alzheimer's disease. J Alzheimers Dis 2012; 29: 615-628.